In first-line metastatic breast cancer, the bevacizumab-taxane to progression or toxicity, is currently the standard treatment. In patients expressing hormone receptors, it was shown that hormone therapy administered in maintenance after induction chemotherapy, could have a benefit regarding the progression-free survival. The investigators make the hypothesis that there would be interest to discontinue treatment with taxane after 4 months, and to begin hormone therapy while continuing maintenance bevacizumab. Exemestane was chosen because it has been shown potentially active in patients who progressed after letrozole, anastrozole or tamoxifen.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
117
IV, 80mg/m² at d1, d8, d15
IV, 10 mg/kg at d1, d15 or IV, 15 mg/kg every 3 weeks
daily 25 mg (1 pill) oral intake
BACHELOT
Lyon, France
Primary free survival
Time frame: 24 months for recruitment and 18 months for follow up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.